Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Inc.; Daiichi Sankyo, Inc.
• Treatments: Colesevelam Hydrochloride

Criteria

Inclusion/Rollover Criteria:

• Patients who have completed studies WEL-301, WEL-302, or WEL-303 with treatment compliance at least 80%

• Patients who have completed studies WEL-301, WEL-302, or WEL-303 who have not met withdrawal criteria